Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Genetically programmable pathogen sense and destroy.

Gupta S, Bram EE, Weiss R.

ACS Synth Biol. 2013 Dec 20;2(12):715-23. doi: 10.1021/sb4000417. Epub 2013 Jul 2.

PMID:
23763381
2.

Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers.

Adar Y, Stark M, Bram EE, Nowak-Sliwinska P, van den Bergh H, Szewczyk G, Sarna T, Skladanowski A, Griffioen AW, Assaraf YG.

Cell Death Dis. 2012 Apr 5;3:e293. doi: 10.1038/cddis.2012.30.

3.

Heterogeneous nuclear ribonucleoprotein H1/H2-dependent unsplicing of thymidine phosphorylase results in anticancer drug resistance.

Stark M, Bram EE, Akerman M, Mandel-Gutfreund Y, Assaraf YG.

J Biol Chem. 2011 Feb 4;286(5):3741-54. doi: 10.1074/jbc.M110.163444. Epub 2010 Nov 10.

4.
5.

Structural determinants of imidazoacridinones facilitating antitumor activity are crucial for substrate recognition by ABCG2.

Bram EE, Adar Y, Mesika N, Sabisz M, Skladanowski A, Assaraf YG.

Mol Pharmacol. 2009 May;75(5):1149-59. doi: 10.1124/mol.109.054791. Epub 2009 Feb 27.

PMID:
19251825
6.

PCFT/SLC46A1 promoter methylation and restoration of gene expression in human leukemia cells.

Gonen N, Bram EE, Assaraf YG.

Biochem Biophys Res Commun. 2008 Nov 28;376(4):787-92. doi: 10.1016/j.bbrc.2008.09.074. Epub 2008 Sep 24.

PMID:
18817749
7.

C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.

Bram EE, Ifergan I, Grimberg M, Lemke K, Skladanowski A, Assaraf YG.

Biochem Pharmacol. 2007 Jun 30;74(1):41-53. Epub 2007 Apr 1.

PMID:
17481587

Supplemental Content

Support Center